The Library
Direct oral anticoagulants for cancer-associated venous thromboembolism : a systematic review and meta-analysis
Tools
Tools
Tools
Mulder, Frits I., Bosch, Floris T. M., Young, Annie M., Marshall, Andrea, McBane, Robert D., Zemla, Tyler, Carrier, Marc, Kamphuisen, Pieter W., Bossuyt, Patrick M., Buller, Harry R., Weitz, Jeffrey I., Middeldorp, Saskia and van Es, Nick (2020) Direct oral anticoagulants for cancer-associated venous thromboembolism : a systematic review and meta-analysis. Blood, 136 (12). pp. 1433-1441. doi:10.1182/blood.2020005819 ISSN 0006-4971.
|
PDF
WRAP-Direct-oral-anticoagulants-cancer-venous-thromboembolism-meta-analysis-Marshall-2020.pdf - Accepted Version - Requires a PDF viewer. Download (1302Kb) | Preview |
Official URL: https://doi.org/10.1182/blood.2020005819
Abstract
Direct oral anticoagulants (DOACs) are an emerging treatment option for cancer patients with acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWH) in these patients. MEDLINE, Embase, CENTRAL, and conference proceedings were searched to identify relevant randomized controlled trials. Additional data were obtained from the original authors to homogenize definitions for all study outcomes. The primary efficacy and safety outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the composite of recurrent VTE and major bleeding, clinically relevant non-major bleeding (CRNMB), and all-cause mortality. Summary relative risks (RR) were calculated in a random effects meta-analysis. In the primary analysis comprising 2,607 patients, the risk of recurrent VTE was non-significantly lower with DOACs than with LMWH (RR 0.68; 95% CI, 0.39 to 1.17). Conversely, the risks of major bleeding (RR 1.36; 95% CI, 0.55 to 3.35) and CRNMB (RR 1.63, 95%, 0.73 to 3.64) were non-significantly higher. The risk of the composite of recurrent VTE or major bleeding was non-significantly lower with DOACs than with LMWH (RR 0.86; 95% CI, 0.60 to 1.23). Mortality was comparable in both groups (RR 0.96; 95% CI, 0.68 to 1.36). Findings were consistent during the on-treatment period and in those with incidental VTE. In conclusion, DOACs are an effective treatment option for cancer patients with acute VTE, although caution is needed in patients at high risk of bleeding. [Abstract copyright: Copyright © 2020 American Society of Hematology.]
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||
| SWORD Depositor: | Library Publications Router | ||||||||
| Library of Congress Subject Headings (LCSH): | Anticoagulants (Medicine), Oral medication, Thromboembolism, Thromboembolism -- Chemotherapy | ||||||||
| Journal or Publication Title: | Blood | ||||||||
| Publisher: | American Society of Hematology | ||||||||
| ISSN: | 0006-4971 | ||||||||
| Official Date: | 17 September 2020 | ||||||||
| Dates: |
|
||||||||
| Volume: | 136 | ||||||||
| Number: | 12 | ||||||||
| Page Range: | pp. 1433-1441 | ||||||||
| DOI: | 10.1182/blood.2020005819 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Reuse Statement (publisher, data, author rights): | ** From PubMed via Jisc Publications Router ** History: received 31-03-2020; accepted 29-04-2020; revised 29-04-2020. | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| Copyright Holders: | Copyright © 2020 American Society of Hematology | ||||||||
| Date of first compliant deposit: | 15 June 2020 | ||||||||
| Date of first compliant Open Access: | 12 May 2021 |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
